Chrysalin Side Effects: Safety Signals and Warnings
Chrysalin safety concerns are compound-specific. The main listed side effects are Well-tolerated in Phase 2 trials, Mild injection site discomfort, and No systemic coagulation effects observed. The main warning signals are Not yet FDA-approved; still in clinical development, Theoretical concern regarding thrombin receptor activation in patients with thrombotic tendencies, and Limited data in patients with impaired healing (diabetes, immunosuppression).
Direct Answer
Chrysalin (TP508) has Phase 2 human data in bone fracture healing showing accelerated radiographic healing, particularly in osteoporotic patients. The thrombin-receptor mechanism is scientifically distinct from other healing peptides. Phase 2 results are promising but Phase 3 data is not yet available. A credible but not yet fully validated healing compound.
- Evidence grade
- Level C
- Research status
- Phase 2
- Category
- Healing & Recovery
- Evidence context
- Bone fracture healing acceleration, osteoporotic fracture recovery, thrombin receptor agonism research
Reported Side Effects
- Well-tolerated in Phase 2 trials
- Mild injection site discomfort
- No systemic coagulation effects observed
- No significant adverse events reported in clinical studies
Warnings
- Not yet FDA-approved; still in clinical development
- Theoretical concern regarding thrombin receptor activation in patients with thrombotic tendencies
- Limited data in patients with impaired healing (diabetes, immunosuppression)
- Long-term safety profile not fully established
Known or Plausible Interactions
- Anticoagulants (theoretical interaction via thrombin receptor pathway, though no coagulation effects observed)
- NSAIDs (may impair bone healing and reduce TP508 efficacy)
- Bone morphogenetic proteins (potential complementary effects)
Regulatory Context
Chrysalin (TP508) is an investigational candidate that has been studied in Phase 2 trials but is not FDA-approved. Any current trial status should be confirmed in a primary registry.
Evidence Snapshot
| Evidence grade | Level C |
|---|---|
| Research status | Phase 2 |
| Best supported outcomes | Bone Fracture Healing (Level C), Soft Tissue Wound Healing (Level D), and Spinal Fusion Enhancement (Level D) |
| Primary citation count | 2 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Chrysalin?
Chrysalin safety concerns are compound-specific. The main listed side effects are Well-tolerated in Phase 2 trials, Mild injection site discomfort, and No systemic coagulation effects observed. The main warning signals are Not yet FDA-approved; still in clinical development, Theoretical concern regarding thrombin receptor activation in patients with thrombotic tendencies, and Limited data in patients with impaired healing (diabetes, immunosuppression).
What is the evidence level for Chrysalin?
Chrysalin is rated Level C. Its current research status is Phase 2.
What is Chrysalin best known for?
Bone fracture healing acceleration, osteoporotic fracture recovery, thrombin receptor agonism research.
Where can I read the full Chrysalin evidence review?
The full evidence review is available at https://examinepeptides.com/library/chrysalin.
Related Guides
How to Cite This Page
ExaminePeptides. "Chrysalin Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/chrysalin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.